Healthcare services company Select Medical (NYSE: SEM) will be reporting earnings this Thursday afternoon. Here’s what to look for.

Select Medical beat analysts’ revenue expectations by 2.7% last quarter, reporting revenues of $1.36 billion, up 7.2% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.

Is Select Medical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Select Medical’s revenue to grow 4.1% year on year to $1.37 billion, slowing from the 7.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.23 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings.

Looking at Select Medical’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. DaVita delivered year-on-year revenue growth of 9.9%, beating analysts’ expectations by 3.2%, and Encompass Health reported revenues up 9.9%, in line with consensus estimates. DaVita traded up 21.2% following the results while Encompass Health was also up 5.9%.

Read our full analysis of DaVita’s results here and Encompass Health’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. Select Medical is up 7.8% during the same time and is heading into earnings with an average analyst price target of $18.40 (compared to the current share price of $16.38).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.